CN105125946A - 一种清心除烦的栀子口服液及其制备方法 - Google Patents
一种清心除烦的栀子口服液及其制备方法 Download PDFInfo
- Publication number
- CN105125946A CN105125946A CN201510655336.6A CN201510655336A CN105125946A CN 105125946 A CN105125946 A CN 105125946A CN 201510655336 A CN201510655336 A CN 201510655336A CN 105125946 A CN105125946 A CN 105125946A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus gardeniae
- oral liquid
- component
- fire
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 66
- 208000001431 Psychomotor Agitation Diseases 0.000 title claims abstract description 31
- 206010038743 Restlessness Diseases 0.000 title claims abstract description 31
- 210000002216 heart Anatomy 0.000 title abstract description 27
- 238000000034 method Methods 0.000 title description 14
- 240000001972 Gardenia jasminoides Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 229940079593 drug Drugs 0.000 claims description 47
- 210000000582 semen Anatomy 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 24
- 230000008901 benefit Effects 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 15
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 241000217407 Margaritifera Species 0.000 claims description 13
- 241000244155 Taenia Species 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 66
- 239000008280 blood Substances 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 32
- 230000028327 secretion Effects 0.000 abstract description 7
- 244000111489 Gardenia augusta Species 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 abstract description 3
- 235000017491 Bambusa tulda Nutrition 0.000 abstract description 3
- 208000003351 Melanosis Diseases 0.000 abstract description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 abstract description 3
- 239000011425 bamboo Substances 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 241000756042 Polygonatum Species 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 1
- 235000011468 Albizia julibrissin Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 235000016854 Cyperus rotundus Nutrition 0.000 abstract 1
- 206010014970 Ephelides Diseases 0.000 abstract 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract 1
- 235000000100 Hibiscus rosa sinensis Nutrition 0.000 abstract 1
- 240000003271 Leonurus japonicus Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000082204 Phyllostachys viridis Species 0.000 abstract 1
- 241001633680 Polygonatum odoratum Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 235000000664 Rosa chinensis Nutrition 0.000 abstract 1
- 235000016785 Rosa della China Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
- 230000036449 good health Effects 0.000 abstract 1
- 230000000630 rising effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 35
- 210000004185 liver Anatomy 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 206010011224 Cough Diseases 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 206010022437 insomnia Diseases 0.000 description 16
- 230000036541 health Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 11
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 10
- 239000010839 body fluid Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 230000035922 thirst Effects 0.000 description 10
- 206010033557 Palpitations Diseases 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000001077 hypotensive effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 8
- 206010003549 asthenia Diseases 0.000 description 8
- 230000001914 calming effect Effects 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002443 hepatoprotective effect Effects 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 206010043458 Thirst Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 6
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000003419 expectorant effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 229940090044 injection Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 235000019615 sensations Nutrition 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 208000015220 Febrile disease Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 210000000232 gallbladder Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000035568 catharsis Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000017574 dry cough Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000036119 Frailty Diseases 0.000 description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 3
- 208000000616 Hemoptysis Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000026137 Soft tissue injury Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000013116 chronic cough Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003912 environmental pollution Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 208000036796 hyperbilirubinemia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 235000014101 wine Nutrition 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- MQBFFYQCZCKSBX-UHFFFAOYSA-N 5-hydroxy-6,7,8-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2OC3=C(OC)C(OC)=C(OC)C(O)=C3C(=O)C=2)=C1 MQBFFYQCZCKSBX-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 235000018958 Gardenia augusta Nutrition 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940010073 hydrocortisone injection Drugs 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- SQMCFUSVGSBKFK-UHFFFAOYSA-M sodium;5-(cyclohexen-1-yl)-1,5-dimethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1N(C)C(=O)[N-]C(=O)C1(C)C1=CCCCC1 SQMCFUSVGSBKFK-UHFFFAOYSA-M 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000209128 Bambusa Species 0.000 description 1
- 241001317485 Bambusa tuldoides Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- WSGPLSDARZNMCW-UHFFFAOYSA-N Deacetylasperulosidsaeure-methylester Natural products OC1C=C(CO)C2C1C(C(=O)OC)=COC2OC1OC(CO)C(O)C(O)C1O WSGPLSDARZNMCW-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229930188400 Gardenin Natural products 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- ZJDOESGVOWAULF-OGJQONSISA-N Geniposidic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=CC[C@@H]2C(C(O)=O)=CO1 ZJDOESGVOWAULF-OGJQONSISA-N 0.000 description 1
- VYAALAFRWREWLA-BVTMAQQCSA-N Geniposidic acid Natural products CCC1=CC[C@H]2[C@@H]1[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C2C(=O)O VYAALAFRWREWLA-BVTMAQQCSA-N 0.000 description 1
- ZJDOESGVOWAULF-UHFFFAOYSA-N Geniposidinsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(CO)=CCC2C(C(O)=O)=CO1 ZJDOESGVOWAULF-UHFFFAOYSA-N 0.000 description 1
- 241000146384 Glaux Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 240000005827 Phyllostachys nigra Species 0.000 description 1
- 235000010717 Phyllostachys nigra Nutrition 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000008254 Rosa chinensis Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 244000068081 Sinocalamus beecheyanus Species 0.000 description 1
- 235000005700 Sinocalamus beecheyanus Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- CGGOYIAWBUQWRM-UHFFFAOYSA-N acetic acid;1h-indol-2-ol Chemical compound CC(O)=O.C1=CC=C2NC(O)=CC2=C1 CGGOYIAWBUQWRM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Natural products CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- -1 hydroxytryptamine creatinine sulfates Chemical class 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 101150087532 mitF gene Proteins 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940081543 potassium bitartrate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000027912 synapse maturation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021228 wine soup Nutrition 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000010124 zhibai dihuang Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
一种清心除烦的栀子口服液,其所述口服液包括以下重量份数的原料药:栀子10~50份,远志10~20份,茯苓10~20份,合欢花10~20份,香附10~20份,玉竹10~20份,益母草10~20份,竹茹10~20份,百合10~20份,生地10~20份,莲芯10~20份,知母10~20份,月季花10~20份,珍珠母10~20份,麦冬10~20份,黄芩10~20份,黄精10~20份,酸枣仁10~20份,柏子仁10~20份。本发明通过通补结合,升降得宜等精妙的处方配伍,以调理人体紊乱的代谢和失调的内分泌,调节机体状态平衡,使脏腑功能活动正常,气血流畅,气机条达,阴阳平衡,益气活血,排毒祛斑,清心除烦,从而达到身体健康与睡眠质量良好的双重功效。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用保健品,特别涉及一种清心除烦的栀子口服液及其制备方法。
背景技术
现代都市人就业压力大,竞争剧烈。应酬多,糟心的事多。房事、孩子上学、养老就医,每一件都费心费力;再加上环境污染日益严重,饮食不健康,所以感觉每天都在上火,每天都在焦躁不安。
求职、升职、住房、加薪、病患、孩子教育,方方面面生活的琐事让现代人心力交瘁,感觉身体入不敷出。再加上现代都市上班族普遍使用电脑办公,烟酒无度,夜生活不节制,熬夜,这些都直接伤害了肝肾。久视以及辐射,为电脑一族的眼睛健康埋下了隐患。这类人需要在注意用眼卫生的同时护肝养血。现代人们的生活饮食过于精细,运动量减少,或暴饮暴食,或劳倦过度,使得人体代谢机能逐渐衰退,导致脏腑功能失调,容易产生睡眠问题。想睡个好觉可能成了很多白领、用脑一族的奢望。
栀子性苦、寒、无毒;气微,味微酸而苦;入心、肝、肺、胃经。栀子花含黄酮类栀子素、果胶、鞣质、藏红花素等,根、叶、花皆可入药,有镇静、降压,抑菌、致泻、镇痛、抗炎,调节平滑肌,加速软组织的愈合等作用,有泻火除烦,消炎祛热,清热利尿,外用解毒之功效。
栀子清热,泻火,凉血。治热病虚烦不眠,黄疸,淋病,消渴,目赤,咽痛,吐血,衄血,血痢,尿血,热毒疮疡,扭伤肿痛。
现在市面上各种养肝护肝、安神补脑的保健品、药品泛滥,但大多数徒有其表,大张旗鼓的虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害,因此,寻找健康有效的保肝护肝、安神补脑的保健品具有很现实的重要意义。中药保肝护肝、安神补脑具有无毒、能被生物体完全吸收的优点,是我们研究的主要方向。
发明内容
本发明所要解决的技术问题在于,环境污染日益严重,求职、升职、住房、加薪、病患、孩子教育,方方面面生活的琐事让现代人心力交瘁,感觉身体入不敷出。现在市面上各种养肝护肝、安神补脑的保健品、药品泛滥,但大多数徒有其表,大张旗鼓的虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害,因此,寻找健康有效的保肝护肝、安神补脑的保健品具有很现实的重要意义。中药保肝护肝、安神补脑具有无毒、能被生物体完全吸收的优点,是我们研究的主要方向。如何满足五脏和体内的清洁,达到清心除烦,健康体魄的。在国外人们一般选择天然、无副作用的产品来解决类似问题。
为解决上述技术问题,本发明提供一种清心除烦的栀子口服液,其所述口服液包括以下重量份数的原料药:栀子10~50份,远志10~20份,茯苓10~20份,合欢花10~20份,香附10~20份,玉竹10~20份,益母草10~20份,竹茹10~20份,百合10~20份,生地10~20份,莲芯10~20份,知母10~20份,月季花10~20份,珍珠母10~20份,麦冬10~20份,黄芩10~20份,黄精10~20份,酸枣仁10~20份,柏子仁10~20份。
所述清心除烦的栀子口服液,其所述口服液中各种原料药的重量份数可以为:栀子10~40份,远志10~15份,茯苓10~15份,合欢花10~15份,香附10~15份,玉竹10~15份,益母草10~15份,竹茹10~15份,百合10~15份,生地10~15份,莲芯10~20份,知母10~20份,月季花10~20份,珍珠母10~20份,麦冬10~20份,黄芩10~20份,黄精10~20份,酸枣仁10~20份,柏子仁10~20份。
所述清心除烦的栀子口服液,其所述口服液中各种原料药的重量份数还可以为:栀子10~30份,远志10~20份,茯苓10~20份,合欢花10~20份,香附10~20份,玉竹10~20份,益母草10~20份,竹茹10~20份,百合10~20份,生地10~20份,莲芯10~15份,知母10~15份,月季花10~15份,珍珠母10~15份,麦冬10~15份,黄芩10~15份,黄精10~15份,酸枣仁10~15份,柏子仁10~15份。
为解决上述技术问题,本发明还提供一种清心除烦的栀子口服液的制备方法,其所述口服液的制备步骤包括:
a.栀子的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
所述步骤a中,可以将收获的栀子洗净,将其浸泡水中1-2小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,成组分1备用。
所述步骤b中,可以将所述其余原料泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
所述步骤c中,可以将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
为解决上述技术问题,本发明再提供一种清心除烦的栀子口服液的制备方法,制备步骤还可以为:
a.栀子的制备,作为组分1;
b.将所述其余原料药加水浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
所述步骤a中,可以将洗净栀子放于10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1;所述步骤b中,可以将所述其余原料放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
所述步骤c中,可以将组分1和组分2的合并,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,调和蜂蜜,紫外线消毒杀菌后装瓶。
本发明将现代营养学理论与传统中医药养生保健理论有机结合,可以补气益血,滋阴补肾、祛斑美白。如何打通人体排毒管道,通过排毒主管道——皮肤将体内毒素排出,并通过通补结合,升降得宜等精妙的处方配伍,以调理人体紊乱的代谢和失调的内分泌,调节机体状态平衡,使脏腑功能活动正常,气血流畅,气机条达,阴阳平衡,益气活血,排毒祛斑,清心除烦,从而达到身体健康与睡眠质量良好的双重功效。
具体实施方式
现代都市人就业压力大,竞争剧烈。应酬多,糟心的事多。房事、孩子上学、养老就医,每一件都费心费力;再加上环境污染日益严重,饮食不健康,所以感觉每天都在上火,每天都在焦躁不安。
烟酒无度,夜生活不节制,熬夜,这些都直接伤害了肝肾。久视以及辐射,为电脑一族的眼睛健康埋下了隐患。这类人需要在注意用眼卫生的同时护肝养血。现代人们的生活饮食过于精细,运动量减少,或暴饮暴食,或劳倦过度,使得人体代谢机能逐渐衰退,导致脏腑功能失调,容易产生睡眠问题。想睡个好觉可能成了很多白领、用脑一族的奢望
药理作用
1.对肝脏功能的影响
①用SD大白鼠分为4组;A组为对照组;B组为正常动物,用2g生药提取物灌胃;C组为结扎总胆管,引起高胆红素血症的动物;D组为高胆红素血症动物,并用2g生药的栀子提取物灌胃。实验测定肝脏Y蛋白、Z蛋白、BSP清除率、胆红素及有关酶的测定。实验结果表明:1)栀子提取物对动物血清和肝匀浆内碱性磷酸酶的活力并无影响,结扎总胆管引起碱性磷酶酶活力增加将近2倍。但栀子提取物对升高了的酶活力并无作用。2)栀子提取物对大白鼠血清和肝内乳酸脱氢酶活力的影响极小,4组动物酶活力的波动均在正常范围之内。3)栀子提取物对正常动物血清GOT无影响。结扎总胆管后,血清GOT增加7倍,栀子提取物可显著降低升高了的酶达40%。肝内GOT较稳定,4组动物均无明显改变。4)栀子提取物对正常动物的酶活力无影响,但能使结扎总胆管动物升高了的酶活力恢复正常,可认为栀子提取物并不增加UDP-GT的活力。5)测定肝脏二磷酸脲苷-葡萄糖脱氢酶表明,结扎总胆管可以降低酶活力,栀子提取物能增加正常动物酶活力,同时也能使降低了的酶活力升高。6)栀子提取物能增加正常动物的Y蛋白、Z蛋白的量,但不能使由于结扎总胆管而减少的Y蛋白、Z蛋白量增加。表明栀子抗胆红素血症作用与Y蛋白、Z蛋白关系不大。7)动物给药后静脉注射BSP(2g/100g体重),测定血液中及胆汁中的BSP清除率,发现到达峰值时间均有相应的延长,表明BSP从肝内排出的过程受到阻滞。8)栀子能降低血清胆红素含量,但与葡萄糖醛酰转移酶无关。因此可以认为栀子提取物对肝细胞无毒性作用,栀子提取物可降低动物血清胆红素水平,但其退黄机制较为复杂,它不增加UDP-GT的活力,也不增加肝内的Y蛋白和之蛋白,也不像茵陈蒿那样,增加胆汁的分沁量。
②肝脏的保护作用
1)ICR大鼠预先(24或48小时以前)给于栀子提取物,可防止因半乳糖胺引起的暴发性肝炎。2)实验大鼠给于异硫氰酸a-萘酯50mg/kg,可使大鼠血清胆红素和血清碱性磷酸酯酶和丙氨酸氨基转移酶升高,如每日给于栀子粗提物(1.5g/kg,口服,3天)可使因异硫氰酸a-萘酯中毒大鼠的血清胆红素、丙氨酸氨基转移酶和碱性磷酸酶下降。栀子中提取的成分栀子甙同样有此作用。3)对肝脏的影响:大鼠灌胃藏红花素50mg/kg8天对肝脏功能无影响,但可引起急性肝脏变色。如服用高剂量100mg/kg2周则可引起肝损害和黑变,但低剂量10mg/kg40天并不产生上述情况,上述的肝损害和黑变是完全可逆的。因此藏红花素即使很高剂量对大鼠肝脏的毒性极小,在人服用时不可能达到如此高的剂量,所以藏红花素作为食品着色剂是十分安全的。
2.对胆汁分泌的影响
大鼠、兔实验证明,栀子具利胆作用。其醇提物和栀子甙、藏红花素等均能使胆汁分泌量增加。大鼠口服、静脉注射或十二指肠内给于栀子甙25mg/kg引起胆汁分泌增加,以十二指肠内给药最为显著,几与去氢胆酸钠的效价相当。
3.对胃液分泌及胃肠运动的影响
十二指肠给予栀子甙25mg/kg,能使幽门结扎大鼠胃液分泌减少,总酸度下降,pH值升高,作用相当于硫酸阿托品的1/5-1/10。静脉注射栀子甙和其甙元(Genipin),剂量分别为100mg/kg与25mg/kg,能抑制大鼠自发性胃蠕动和匹罗卡品(Pilocarpine)诱发的胃收缩,但作用短暂。低浓度(1∶25,000)栀子醇提取物能兴奋大鼠、兔小肠运动,高浓度(1∶1,000)则抑制。小鼠和豚鼠离体回肠试验表明栀子甙有较弱的抗乙酰胆碱和抗组胺作用。
4.促进胰腺分泌作用
杨稚珍等用胆胰插管研究栀子及其不同提取物对大鼠胆胰流量及胰酶活性的影响,结果显示,栀子及其几种提取物有明显的利胰、利胆及降胰酶效应。京尼平甙有最显著的降低胰淀粉酶作用,而其酶解产物京尼平的增加胰胆流量作用最强,持续时间较短。裴德恺的研究认为栀子促进胰腺分泌作用可能与保持胰细胞膜的结构、功能直接有关,从而从细胞水平上论证了栀子治疗胰腺炎的药效基础。初步观察亦发现栀子有使膜脂的过氧化产物减少作用。
5.对中枢神经系统的作用
小鼠腹腔注射栀子醇提取物(栀子果实粉碎后以乙醇渗漉,渗漉液在50℃减压浓缩去醇,制成300%浓缩液)5.69g/kg,能减少小鼠自发活动(踏板法),与对照组相比较P<0.01,且与环己比妥钠(静脉注射,50mg/kg)有协同作用,能延长睡眠时间近12倍。但如用药组小鼠灌胃35g/kg栀子醇渗漉液,然后分别在1.2.3小时,静脉注射环己烯巴比妥钠50mg/kg,记录翻正反射消失时间,结果只有于2小时给药的栀子组能显著延长环己烯巴比妥钠睡眠时间(P<0.05)。但栀子对苯丙胺诱发活动无对抗作用。小鼠腹腔注射栀子醇提物5.69g/kg,体温可平均降低3℃,大鼠腹腔注射200mg/kg体温下降可持续7小时以上。
6.对心血管系统的作用
栀子煎剂和醇提物对麻醉或不麻醉猫、兔、大鼠,不论口服,腹腔注射或静脉注射给药均有降压作用,其降压作用对肾上腺素升压作用及阻断颈动脉血流的加压反射均元影响。也没有加强乙酰胆碱的降压作用。给予抗组胺药如苯海拉明,对栀子的降血压作用无影响。其降压作用不是由于释放组胺所引起。静脉注射普鲁卡因也不改变栀子的降血压效果,说明其降血压作用与传入神经纤维无关。对神经节无阻断作用。当切断两侧迷走神经后,栀子的降血压作用显著减弱或完全消失,阿托品也可取消其降血压作用。故认为栀子的降血压作用部位在中枢,栀子降血压效应主要是加强了延脑副交感中枢紧张度所致。亦有报道栀子对外周阻力影响不大,离体鼠心灌流实验表明,栀子提取物能降低心肌收缩力。麻醉犬、鼠静脉注射栀子提取物500mg/kg引起的血压下降是由于心收缩容积及心输出量下降。Im藏红花酸(藏红花素的水解产物)0.01mg/kg,能减少喂饲胆固醇兔动脉硬化的发生率。大鼠静脉注射大剂量1g/kg的栀子甲醇提取物时,心电图可呈现心肌损伤及房室传导阻滞。但麻醉兔静脉注射栀子甙30mg/kg,对血压、心率和乙电图都无明显影响。栀子果实的热水提取物能刺激体外培养牛主动脉内皮细胞的增殖,从而使血管内膜得以修复。
7.抑菌作用
栀子煎剂对白喉杆菌、金黄色葡萄球菌、伤寒杆菌有抑制作用,对多种皮肤真菌也有不同程度的抑制作用。
8.致泻作用
去乙酰车叶草甙酸甲酯有泻下作用,小鼠的半数有效量为0.53g/kg,服用6小时后开始腹泻。羟异栀子甙亦有导泻作用,小鼠口服的半数有效量为1.2g/kg,服后3小时开始作用。栀子甙的导泻作用半数有效量为300mg/kg,服药后3小时起作用。栀子甙酸的导泻作用半数有效量>800mg/kg。
9.镇痛作用
栀子甙及其水解产物京尼平对腹腔注射醋酸引起的小鼠扭体运动有抑制作用。
10.抗炎及治疗软组织损伤的作用
栀子以乙醇回流提取,在40℃以下减压浓缩至粘稠膏状(G1);将乙醇回流提取后的药渣,用水渗漉,渗漉液水浴蒸干(G2);将G1部分以甲醇溶解加硅藻土拌匀,以不同有机溶剂洗脱,分别回收溶剂得石油醚部分(G3),氯仿部分(G4),乙酸乙酯部分(G5),甲醇部分(G6)。
然后以栀子甙(C-A),氢化可的松软膏(H-U),氢化可的松注射剂(H-I),外伤止痛膏(H-E)作为对照。观察栀子各分离部位对软组织损伤动物模型的治疗作用和抗炎作用。结果如下:栀子各分离部分对软组织损伤模型的治疗作用。
黄精以根茎入药。具有补气养阴,健脾,润肺,益肾功能。用于治疗脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴等症。对于糖尿病很有疗效。酒黄精又称炙黄精。为净黄精加酒和黑豆等辅料蒸后切片晒干入药者。兼有遁经络之功。黄精具有降血压,降血糖,降血脂,防止动脉粥样硬化,延缓衰老和抗菌等作用,黄精多糖具有免疫激活作用。用于阴虚肺燥,干咳少痰,及肺肾阴虚的劳嗽久咳等。用于脾胃虚弱。既补脾阴,又益脾气,用于肾虚精亏得头晕,腰膝酸软,须发早白及消渴等。黄精壮筋骨,益精髓,变白发;适宜用于肺阴不足所致的咳嗽痰少,干咳无痰,咳血等症。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
香附辛微苦甘,平功能主治:理气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛。《纲目》载其:散时气寒疫,利三焦,解六郁,消饮食积聚,痰饮痞满,跗肿,腹胀,脚气,止心腹、肢体、头、目、齿、耳诸痛,痈疽疮疡,吐血,下血,尿血,妇人崩漏带下,月候不调,胎前产后百病。
益母草味辛苦、凉。活血、祛淤、调经、消水。治疗妇女月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血、泻血,痈肿疮疡。益母草含益母草碱、延胡索酸等物质,有活血调经、降血压、利尿消肿等作用。
玉竹:滋阴润肺;养胃生津。燥咳;劳嗽;热病阴液耗伤之咽干口渴;内热消渴;阴虚外感;头昏眩晕;筋脉挛痛。玉竹味甘多脂,质柔而润,是一味养阴生津的良药。玉竹中所含的维生素A,改善干裂、粗糙的皮肤状况,使之柔软润滑。起到美容护肤的作用。《本草经集注》云“茎干强直,似竹箭杆,有节。”故有玉竹之名。植物的根茎可供药用,中药名亦为玉竹,秋季采挖,洗净,晒至柔软后,反复揉搓,晾晒至无硬心,晒干,或蒸透后,揉至半透明,晒干,切厚片或段用。《本草正义》:“治肺胃燥热,津液枯涸,口渴嗌干等症,而胃火炽盛,燥渴消谷,多食易饥者,尤有捷效”。
合欢花含有合欢甙,鞣质,解郁安神,理气开胃,活络止痛,用于心神不安、忧郁失眠。治郁结胸闷,失眠,健忘,风火眼,能安五脏,和心志,悦颜色,有较好的强身、镇静、安神、美容的作用,也是治疗神经衰弱的佳品。也具有清热解暑,养颜祛斑解酒等功效。《本草经》说:“合欢花能安五脏,和心志,悦颜色。”尤其对孕妇,有较好的强身、镇静、安神、美容的作用,也是治疗神经衰弱的佳品。
月季花,中药名。为蔷薇科植物月季RosachinensisJacq.的干燥花。全年均可采收,花微开时采摘,阴干或低温干燥。均为栽培。具有活血调经,疏肝解郁之功效。常用于气滞血瘀,月经不调,痛经,闭经,胸胁胀痛。
竹茹,中药名。为禾本科植物青秆竹BambusatuldoidesMunro、大头典竹Sinocalamusbeecheyanus(Munro)McClurevar.pubescensP.F.Li或淡竹PhyILostachysnigra(Lodd.)Munrovar.henonis(Mitf.)StapfexRendle的茎秆的干燥中间层。具有清热化痰,除烦,止呕的功效。用于痰热咳嗽,胆火挟痰,惊悸不宁,心烦失眠,中风痰迷,舌强不语,胃热呕吐,妊娠恶阻,胎动不安。《本草纲目》:伤寒劳复,小儿热痫,妇人胎动。《药性论》:止肺痿唾血,鼻衄,治五痔。
百合除含有蛋白质21.29%、脂肪12.43%、还原糖11.47%、淀粉1.61%,及钙、磷、铁、每百克含1.443毫克维生素B、21.2毫克维生素C等营养素外,还含有一些特殊的营养成分,如秋水仙碱等多种生物碱。这些成分综合作用于人体,不仅具有良好的营养滋补之功,而且还对秋季气候干燥而引起的多种季节性疾病有一定的防治作用。中医上讲鲜百合具有养心安神,润肺止咳的功效,对病后虚弱的人非常有益。《本经》:主邪气腹胀、心痛。利大小便,补中益气。《别录》:除浮肿胪胀,痞满,寒热,通身疼痛,及乳难,喉痹,止涕泪。《药性论》:除心下急、满、痛,治脚气,热咳逆。
莲芯,即莲子心,中药名。为睡莲科多年生水生草本植物莲成熟种子中的幼叶及胚根。秋季采收莲子时,将莲子剥开,取出绿色胚(莲芯),晒干。具有清心火,平肝火,止血,固精之功效。《随息居饮食谱》:敛液止汗,清热养神,止血固精。
知母为著名中药,性苦寒,有滋阴降火、润燥滑肠、利大小便之效。属清热下火药,主治:温热病、高热烦渴、咳嗽气喘、燥咳、便秘、骨蒸潮热、虚烦不眠、消渴淋浊。用于阴虚火旺,肺肾亏所致的骨节蒸潮热、盗汗、心烦等症。知母有滋阴降火的作用。常同黄柏相须为用,配入养阴药中,如知柏地黄丸。可用于阴虚消渴,症见口渴、饮多、尿多者。本品有滋阴润澡、生津止渴功效。同天花粉、五味子等配合使用可增强疗效,如玉液汤。清热泻火:用于高热烦渴,常配生石膏;用于肺热咳嗽,常配贝母。滋阴降火:用于阴虚之发热、盗汗,常配黄柏、地黄。《本经》:主消渴热中,除邪气肢体浮肿,下水,补不足,益气。《别录》:疗伤寒久疟烦热,胁下邪气,膈中恶及风汗内疸。
麦冬甘,微苦,微寒。归心、肺、胃经。功能与主治:养阴生津,润肺清心。用于肺燥干咳,阴虚痨嗽,喉痹咽痛,津伤口渴,内热消渴,心烦失眠,肠燥便秘。为百合科植物麦冬的块根,临床常用品有去心与不去心之分,去心之说最早见于陶弘景《名医别录》,谓麦冬如不去心可令人心烦。然后世医家反对者众多,如吴鞠通每用麦冬则注明不去心,谓麦冬有心可以心入心,直清心经之热。笔者认为似无争论之必要,由于中国各地用药习惯不同,可入乡随俗,不必苛求。如欲用其入心清热,可用朱砂拌之,称为辰麦冬。麦冬性寒质润,滋阴润燥作用较好,适用于有阴虚内热、干咳津亏之象的病证,不宜用于脾虚运化失职引起的水湿、寒湿、痰浊及气虚明显的病证。临床将麦冬当作补品补益虚损应注意辨证,用之不当会生湿生痰,出现痰多口淡、胃口欠佳等不良反应。
柏子仁性平味甘,心、肾、大肠经。具养心安神、润肠通便的功效。治惊悸、失眠、遗精、盗汗、便秘等症,能养心安神,润肠通便。用于虚烦不眠,心悸怔忡,肠燥使秘等症。《药品化义》:柏子仁,香气透心,体润滋血。同茯神、枣仁、生地、麦冬,为浊中清品,主治心神虚怯,惊悸怔仲,颜色憔悴,肌肤燥痒,皆养心血之功也。又取气味俱浓,浊中归肾,同熟地、龟版、枸杞、牛膝,为封填骨髓,主治肾阴亏损,腰背重病,足膝软弱,阴虚盗汗,皆滋肾燥之力也。味甘亦能缓肝,补肝胆之不足,极其稳当,但性平力缓,宜多用之为妙。
酸枣仁中国最早的一部药书《神农本草经》中记载:“补中益肝,坚筋骨,助阴气,皆酸枣仁之功也。”明代李时珍《本草纲目》中记载,枣仁“熟用疗胆虚不得眠,烦渴虚汗之症;生用疗胆热好眠,皆足厥阴少阳药也。功效养肝,宁心,安神,敛汗。治虚烦不眠,惊悸怔忡,烦渴,虚汗。《本经》:主心腹寒热,邪结气聚,四肢酸疼,湿痹。《别录》:主烦心不得眠,脐上下痛,血转久泄,虚汗烦渴,补中,益肝气,坚筋骨,助阴气,令人肥健。《药性论》:主筋骨风,炒末作汤服之。《本草拾遗》:睡多生使,不得睡炒熟。王好古:治胆虚不眠,寒也,炒服;治胆实多睡,热也,生用。《本草汇言》:敛气安神,荣筋养髓,和胃运脾。《本草再新》:平肝理气,润肺养阴,温中利湿,敛气止汗,益志定呵,聪耳明目。药理作用:.镇静、催眠作用:酸枣仁煎剂给大白鼠口服或腹腔注射均表现镇静及嗜眠,无论白天或黑夜,酸枣仁均能表现上述作用。小白鼠口服时的镇静指数为1.95,与巴比妥类药物表现协同作用,酸枣仁被连续使用6天后,动物睡眠会变浅,持续时间缩短,即产生耐受性,但停药1周后可消失。
珍珠母是贝类珍珠母层的粉末,具有平肝潜阳;安神定惊;清肝明目的功效。成、寒。归肝、心经。平肝潜阳;安神定惊;清肝明目考证。功用主治平肝,潜阳,定惊,止血。治头眩,耳鸣,心悸,失眠,癫狂,惊痫,吐血,衄血,妇女血崩。《中国医学大辞典》:滋肝阴,清肝火。治癫狂惊痫,头眩,耳鸣,心跳,胸腹膜胀,妇女血热,血崩,小儿惊搐发痉。《饮片新参》:平肝潜阳,安神魂,定惊痫,消热痞、眼翳。
生地:生地也叫生地黄,玄参科多年生草本植物地黄RehmanniaglutinosaLibosch.的新鲜或干燥的块根。清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、金疮瘀、凉血、止血;鲜地黄和生地黄的作用是有所不同的。鲜地黄清热生津,可以止血和凉血,经常是用于热病伤阴,吐血、咽喉肿痛、舌绛烦渴、发斑发疹以及衄热等病症。相对于鲜地黄,生地黄是凉血清热,也可以生津,还可以养阴,多用于治疗阴虚内热、骨蒸劳热、舌绛烦渴、发斑发疹等问题。生地性寒,功能为滋阴补肾。不只生津止渴和凉血清热,还对血崩、月经不调、胎动不安、便秘等有作用,凡是血分有热伤阴的人,都可以经常服用。如果想要治疗温热病,可以用生地做清营汤;如果是治疗温病的后期,由于余热还没消尽,应该把生地用来煮青蒿鳖甲汤。
远志(RadixPolygalae)为常用中药,最早记载于《神农本草经》,列为上品,并被视为养命要药,来源于远志科植物远志PolygalatenuifoliaWilld.和卵叶远志P.sibiricaL.的干燥根。性温,味苦、辛,具有安神益智、祛痰、消肿的功能,用于心肾不交引起的失眠多梦、健忘惊悸,神志恍惚,咳痰不爽,疮疡肿毒,乳房肿痛。《神农本草经》:主咳逆伤中,补不足,除邪气,利九窍,益智慧,耳目聪明,不忘,强志倍力。
黄芩其以根入药,味苦、性寒,有清热燥湿、泻火解毒、止血、安胎等功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床抗菌性比黄连好,而且不产生抗药性。《本草纲目》:治风热湿热头疼,奔豚热痛,火咳肺痿喉腥,诸失血。《别录》:疗痰热胃中热,小腹绞痛,消谷,利小肠,女子血闭,淋露下血,小儿腹痛。
本发明具体实施方式
具体实施例1:
将晾晒好的栀子泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
将其余原料药远志,茯苓,合欢花,香附,玉竹,益母草,竹茹,百合,生地,莲芯,知母,月季花,珍珠母,麦冬,黄芩,黄精,酸枣仁,柏子仁,放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为80℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例2:
将晾晒好的栀子5000g泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
将远志1500g,茯苓1500g,合欢花1500g,香附1500g,玉竹1500g,益母草1500g,竹茹1500g,百合1500g,生地1500g,莲芯1500g,知母1500g,月季花1500g,珍珠母1500g,麦冬1500g,黄芩1500g,黄精1500g,酸枣仁1500g,柏子仁1500g,将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.35的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例3:将晾晒好的栀子4000g浸泡水中1小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,成组分1,将所述其余原料远志1200g,茯苓1300g,合欢花1200g,香附1300g,玉竹1100g,益母草1200g,竹茹1200g,百合1100g,生地1100g,莲芯1200g,知母1200g,月季花1200g,珍珠母1200g,麦冬1100g,黄芩1200g,黄精1200g,酸枣仁1200g,柏子仁1200g,放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例4:将晾晒好的栀子3500g泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。将远志1100g,茯苓1100g,合欢花1200g,香附1100g,玉竹1100g,益母草1200g,竹茹1200g,百合1100g,生地1100g,莲芯1200g,知母1200g,月季花1200g,珍珠母1200g,麦冬1100g,黄芩1200g,黄精1200g,酸枣仁1200g,柏子仁1200g,,将所述原料药放入粉碎机粉碎后,将颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置,将上述两种提取液合并,作为组分2;合并组分1组分2减压浓缩相对密度为80℃时1.36的滤液,回收乙醇,调入蜂胶,紫外线杀菌后装瓶。
试验例1:本发明急性毒性试验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。药物:本发明口服液(按实施方法2制备)。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将栓剂溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将栓剂加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
试验例2:本发明急性皮肤刺激试验报告
1、实验目的:检测本发明对实验动物皮肤的刺激/腐蚀作用和强度
2、材料和方法:
2.1.受试物:本发明口服液(按实施例方法2制得)
2.2.实验动物:壹级大耳白种家兔,10只,雌性,体重2.1-2.3kg;由青岛大学医学院生物系实验动物中心提供;
2.3.试验方法:
选用皮肤完好的健康家兔10只,于试验前24小时将其背部脊柱两侧被毛剪掉,去毛面积左、右各约4cm×4cm。试验时取受试物0.2ml涂于2.5cm×2.5cm的二层纱布上,敷贴于一侧去毛皮肤表面,油纸覆盖,胶布固定。另一侧皮肤作为空白对照。封闭4小时后,去除覆盖物,并用温水清洗去残留受试物,于去除受试物后的1、24和48小时观察涂抹部位皮肤反应,并评分。
3、实验结果:实验动物皮肤未出现任何红斑,红肿,发炎现象。
4、小结:根据《消毒技术规范》(1999)中皮肤刺激反应评分标准判定,本发明对动物皮肤刺激强度属无刺激性。
实施例3:长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明口服液溶液0.2、0.4和0.8ml,分别含生药92、184和368mg,另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药口服液长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。
试验结果表明:本发明口服液实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
药理学实验:
本发明口服液是由栀子、远志,茯苓,合欢花,香附,玉竹,益母草,竹茹,百合,生地,莲芯,知母,月季花,珍珠母,麦冬,黄芩,黄精,酸枣仁,柏子仁,等药物制成的复方口服液,具有健脑安神,生精补髓,清肝明目、清心除烦的功效,用于神经衰弱、失眠、健忘、头晕等症。本文观察了本发明口服液对未成年小鼠学习记忆能力及脑内单胺类神经递质5-HT,DA,NA,5-HIAA含量的影响。
1试验材料
1.1药物本发明口服液,由本院药剂科按实施例2的方法制备;阳性对照药,安神健脑液,北京同仁堂科技发展股份有限公司制药厂生产,批号:4152850。
1.2动物昆明种小鼠11~15g,雌雄各半,购自长春生物制品研究所,许可证号:SCXK.2002.0001。
1.3仪器Y.型水迷宫;ES.180电子分析天平,沈阳龙腾公司生产;RF.540型荧光分光光度计,日本岛津公司生产。
1.4试剂5.羟色胺硫酸肌酐,中国医药公司上海化学试剂采购供应站,批号:65-02.28,瑞士进口分装,纯度99%;5.羟吲哚乙酸,Sigma产品,批号:60k1083,纯度98%~100%;重酒石酸钾去甲肾上腺素,上海禾丰制药有限公司出品,批号:0205037,2mg/mL;盐酸多巴胺,由上海禾丰制药有限公司出品,批号:0204011,20mg/2mL;其它试剂均为国产分析纯。
2方法与结果
对未成年小鼠学习记忆能力的影响(水迷宫法)取小鼠80只,随机分为:空白对照组,安神健脑液13mL/kg给药组,本发明口服液组10.0,5.0,2.5mL/kg3个剂量给药组。每天给药1次,连续给药15d,于初次给药的第11d开始将小鼠置于水迷宫中进行训练。实验采用Y.型水迷路装置。该装置分长臂端和两分枝短臂端。左侧短臂端装有平台,作为小鼠栖身之处,平台上方有灯光照明。三个枝臂端留有一个10cm的开口,中间部分用黑色有机玻璃盖上,作为暗道。水深10cm,水温(30±2)℃,共训练5d,每只动物每天训练10次,训练时将小鼠的尾部朝向迷宫的双叉端轻轻地放入水中,以其在15S内直接达到有光源的平台为正确反应,否则视为错误,记录每只动物每天发生错误的次数,并计算5d平均成绩。实验数据以-X±S表示,组间比较用样本2.1均数t检验方法,结果见表1。
表1本发明口服液对未成年小鼠学习记忆能力的影响(x±s,n=16)
注:与空白对照组比*P<0.05,**P<0.01,***P<0.001,以下各表均同。
由表1结果可见,本发明10.0mL/kg剂量组,于训练的第3d开始便能明显地减少小鼠的错误次数,且随着给药时间的延长,错误次数逐渐减少,说明其可增强小鼠学习记忆能力。
2.2对未成年小鼠脑内单胺类递质含量的影响
取小鼠80只,同上分组给药,连续给药15d,末次给药后1h将动物处死,迅速取脑组织,立即放入液氮灌内冷冻,分批取出匀浆,按荧光分光光度法测定小鼠脑组织中5-HT,DA,NA,5-HIAA的含量,实验数据以x±s表示,组间比较用样本均数t检验方法,结果见表2。
表2本发明口服液对未成年小鼠脑内单胺类递质含量的影响(x±s,n=16)
由表2结果可见,本发明口服液能明显地增加小鼠大脑组织中5-HT,DA,NA含量。
2.3对未成年小鼠胸腺、脾、肾上腺指数的影响取小鼠80只,同2.1分组给药,末次给药后1h将动物处死,取胸腺、脾、肾上腺称重计算脏器指数,实验数据以x±s表示,组间比较用样本均数t检验方法,结果见表3。
表3本发明口服液对未成年小鼠相关脏器指数的影响(x±s,n=16)
由表3结果可见,本发明能明显地增加肾上腺指数。
3讨论
学习记忆是脑的高级功能之一,是衡量动物智力发育的重要指标,学习记忆是通过神经系统一系列生理生化过程实现的。单胺类神经递质对注意力,记忆力和反应能力有着重要的调节作用,它包括NA,DA,5-HT,5-HIAA等,突触中NA,DA,5-HT含量丰富,它不仅与突触传递有关,而且与突触成熟有关。NA,DA,5-HT,5-HIAA的减少,必然影响脑内神经递质的平衡,导致智力损伤而减退。实验结果表明,安神补脑液能增强未成年小鼠的学习记忆能力,同时还表明其可提高动物脑内NA,DA,5-HT的含量,安神补脑液在I缶床上已应用多年,作用明显,疗效确切,但对其用于治疗健忘的作用机制从未进行深入的研究,本文从对未成年动物脑内单胺类神经递质方面的影响结果提示,安神补脑液可能通过激活脑代谢,增加大脑皮质中多种神经介质的数量,从而达到增强记忆的功能。实验结果还显示安神补脑液可增加未成年小鼠肾上腺重量,给药组与对照组有明显差异,这也可能与其方中含有黄精等补肾药有关。
具体实施例:段某,男,27岁。自述工作压力大。脱发严重,面色晦暗。平素爱琢磨事,睡眠质量差。换个工作后,压力徒增,每日睡眠不安,烦躁异常,摔东西,爱吵架,无名火泛滥。口臭加剧,失眠健忘。逐渐加剧,睡觉时经常哭喊,躁动不安,几乎每夜必发,大把落发。2月前开始出现入睡后1小时左右突然坐起,面部表情恐怖、似见异物状,伴有心悸、全身汗出。今来我处就诊。诊断舌红、苔薄黄,脉细数。证属心肝火旺,阴血不足。治宜平肝宁心,安神定志。方用:栀子25g,远志11g,茯苓12g,合欢花13g,香附12g,玉竹11g,益母草12g,竹茹13g,百合12g,生地12g,莲芯11g,知母12g,月季花13g,珍珠母12g,麦冬11g,黄芩12g,黄精11g,酸枣仁12g,柏子仁12g,制成口服液,分早、中、晚3次口服。连服15天。复诊,诉服药后夜惊发作次数大减,口臭减轻,烦躁减轻,入睡后己不再坐起,能一觉睡到天亮,脑子也不再胡思乱想,几乎不再噩梦连连。精力充沛,不再无名火泛滥。前方再进30天后,诸症皆平,睡眠安稳,一直未复发。
Claims (10)
1.一种清心除烦的栀子口服液,其特征在于,所述口服液包括以下重量份数的原料药:栀子10~50份,远志10~20份,茯苓10~20份,合欢花10~20份,香附10~20份,玉竹10~20份,益母草10~20份,竹茹10~20份,百合10~20份,生地10~20份,莲芯10~20份,知母10~20份,月季花10~20份,珍珠母10~20份,麦冬10~20份,黄芩10~20份,黄精10~20份,酸枣仁10~20份,柏子仁10~20份。
2.根据权利要求1所述清心除烦的栀子口服液,其特征在于,所述口服液中各种原料药的重量份数为:栀子10~40份,远志10~15份,茯苓10~15份,合欢花10~15份,香附10~15份,玉竹10~15份,益母草10~15份,竹茹10~15份,百合10~15份,生地10~15份,莲芯10~20份,知母10~20份,月季花10~20份,珍珠母10~20份,麦冬10~20份,黄芩10~20份,黄精10~20份,酸枣仁10~20份,柏子仁10~20份。
3.根据权利要求1所述清心除烦的栀子口服液,其特征在于,所述口服液中各种原料药的重量份数为:栀子10~30份,远志10~20份,茯苓10~20份,合欢花10~20份,香附10~20份,玉竹10~20份,益母草10~20份,竹茹10~20份,百合10~20份,生地10~20份,莲芯10~15份,知母10~15份,月季花10~15份,珍珠母10~15份,麦冬10~15份,黄芩10~15份,黄精10~15份,酸枣仁10~15份,柏子仁10~15份。
4.一种如权利要求1~3中任一项所述清心除烦的栀子口服液的制备方法,其特征在于,所述口服液的制备步骤包括:
a.栀子的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
5.根据权利要求4所述清心除烦的栀子口服液的制备方法,其特征在于,所述步骤a中,将收获的栀子洗净,将其浸泡水中1-2小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,成组分1备用。
6.根据权利要求4所述清心除烦的栀子口服液的制备方法,其特征在于,所述步骤b中,将所述其余原料泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
7.根据权利要求4所述清心除烦的栀子口服液的制备方法,其特征在于,所述步骤c中,将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
8.一种如权利要求1~3中任一项所述清心除烦的栀子口服液的制备方法,其特征在于,制备步骤还可以为:
a.栀子的制备,作为组分1;
b.将所述其余原料药加水浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
9.根据权利要求8所述清心除烦的栀子口服液的制备方法,其特征在于,所述步骤a中,将洗净栀子放于10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1;所述步骤b中,将所述其余原料放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
10.根据权利要求8所述清心除烦的栀子口服液的制备方法,其特征在于,所述步骤c中,将组分1和组分2的合并,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,调和蜂蜜,紫外线消毒杀菌后装瓶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510655336.6A CN105125946A (zh) | 2015-10-12 | 2015-10-12 | 一种清心除烦的栀子口服液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510655336.6A CN105125946A (zh) | 2015-10-12 | 2015-10-12 | 一种清心除烦的栀子口服液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125946A true CN105125946A (zh) | 2015-12-09 |
Family
ID=54711757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510655336.6A Pending CN105125946A (zh) | 2015-10-12 | 2015-10-12 | 一种清心除烦的栀子口服液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125946A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105961963A (zh) * | 2016-03-30 | 2016-09-28 | 黄山树德堂食品饮料有限公司 | 一种金银花保健饮料及制备方法 |
| CN107485020A (zh) * | 2017-08-18 | 2017-12-19 | 武汉华士特工业生物技术开发有限公司 | 一种具有美白功能的口服液及其制备方法 |
| CN108379357A (zh) * | 2018-05-29 | 2018-08-10 | 广东省体育科学研究所 | 一种治疗睡眠障碍中药复方制剂及其制备方法 |
| CN108497100A (zh) * | 2018-02-22 | 2018-09-07 | 安徽中盛食用油科技有限公司 | 一种去烦安神山茶油及其加工方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208302A (zh) * | 2014-08-26 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种降血脂的金樱子保健口服液及其制备方法 |
| CN104324329A (zh) * | 2014-11-20 | 2015-02-04 | 青岛恒波仪器有限公司 | 一种安神补脑的桑葚口服液及其制备方法 |
-
2015
- 2015-10-12 CN CN201510655336.6A patent/CN105125946A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208302A (zh) * | 2014-08-26 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种降血脂的金樱子保健口服液及其制备方法 |
| CN104324329A (zh) * | 2014-11-20 | 2015-02-04 | 青岛恒波仪器有限公司 | 一种安神补脑的桑葚口服液及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 东红 等: "佛手养心安神汤治疗神经衰弱症76例", 《中医研究》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105961963A (zh) * | 2016-03-30 | 2016-09-28 | 黄山树德堂食品饮料有限公司 | 一种金银花保健饮料及制备方法 |
| CN107485020A (zh) * | 2017-08-18 | 2017-12-19 | 武汉华士特工业生物技术开发有限公司 | 一种具有美白功能的口服液及其制备方法 |
| CN108497100A (zh) * | 2018-02-22 | 2018-09-07 | 安徽中盛食用油科技有限公司 | 一种去烦安神山茶油及其加工方法 |
| CN108379357A (zh) * | 2018-05-29 | 2018-08-10 | 广东省体育科学研究所 | 一种治疗睡眠障碍中药复方制剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
| CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
| CN104398986A (zh) | 一种安神补脑的淫羊藿口服液及其制备方法 | |
| CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
| CN103749822B (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
| CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
| CN103520621B (zh) | 一种治疗老年性白内障的中药组合物及其制备方法 | |
| CN103041264B (zh) | 一种防治血管性痴呆葛根补脑益智口服液及其制备方法 | |
| CN104305205A (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
| CN104365943A (zh) | 一种降糖降脂的槐角茶及其制备方法 | |
| CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
| CN105125946A (zh) | 一种清心除烦的栀子口服液及其制备方法 | |
| CN104472789A (zh) | 一种润肠通便的槐角茶及其制备方法 | |
| CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
| CN103749824A (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
| CN105831543A (zh) | 一种平肝明目的菊花保健饮料及其制备方法 | |
| CN104365942A (zh) | 一种桑葚清肝明目保健茶及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN104473153B (zh) | 一种美容养颜的桑葚口服液及其制备方法 | |
| CN104324329A (zh) | 一种安神补脑的桑葚口服液及其制备方法 | |
| CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 | |
| CN104888158A (zh) | 一种提高免疫力的罗布麻叶口服液及其制备方法 | |
| CN105394282A (zh) | 一种可降压降糖降脂的葛根保健茶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151209 |
|
| RJ01 | Rejection of invention patent application after publication |